purely speculation, page-22

This US fund may not be the only fund willing to participate...................maybe just the first to negotiate a deal........?




ASX/Media Release
Monday 11th May 2009
PRIMA BIOMED TO COMMENCE DISCUSSIONS WITH POTENTIAL NORTH
AMERICAN INVESTMENT PARTNERS
Australian health care company Prima BioMed (Prima) (ASX: PRR) is pleased to
announce that it will commence discussions with potential major North American
institutional investment funds later this month for the development of its core product,
the CVac™ ovarian cancer therapy vaccine.
On the back of the continued strong progress towards the commercialisation of
CVac™, the Company has received significant interest from a number of major
institutional investment groups, and Prima’s executive director, Mr Martin Rogers, will
begin discussions in North America with a number of hedge funds and other biotechfocused
investment funds on new investment and partnering opportunities for the
comercialisation of CVac™.